{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:01:18Z","timestamp":1773932478598,"version":"3.50.1"},"reference-count":81,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: Therapeutic agents for cancer can cause unique pulmonary toxicities and mimic other conditions. The advent of new targeted molecular and immune therapies has changed the landscape of cancer treatment. These adverse events pose diagnostic and therapeutic challenges. This review aims to summarize the clinical presentations, radiographic patterns, and management strategies for noninfectious pulmonary complications associated with cancer therapies. Materials and methods: A literature review was conducted focusing on drug-induced lung injury (DILI), radiation-induced lung injury (RILI), pleural disease, pulmonary vascular complications, and other inflammatory conditions in patients with cancer. The data sources included clinical trials, guideline recommendations, observational studies, and expert consensus addressing incidence, pathophysiology, imaging findings, and treatment approaches. Results: Noninfectious pulmonary sequelae of anti-neoplastic therapies encompass a broad spectrum of etiologies. DILI occurs in up to 30% with variable onset and severity. The patterns can be diverse but include interstitial pneumonitis, organizing pneumonia, and diffuse alveolar damage. RILI is common and influenced by the radiation dose, volume, and concurrent therapies, and it may have both acute and chronic clinical and radiographic presentations. Pleural disease may arise from radiation and other agents, and the determination of etiology can impact management. Pulmonary vascular disease arises from many different etiologies, including therapies such as tyrosine kinase inhibitors and proteosome inhibitors, thromboembolic disease, as well as rare processes, including pulmonary veno-occlusive disease. Other conditions such as transfusion-related lung injury, cryptogenic organizing pneumonia, and interstitial lung abnormalities can also further complicate the diagnosis. Conclusions: Noninfectious pulmonary complications related to cancer therapies are diverse and often indistinguishable from infectious or malignant processes. The integration of clinical history, imaging, and selective invasive testing are needed for a timely diagnosis. Management typically involves withdrawal of the offending agent and corticosteroids, with immunosuppressive therapy reserved for severe or refractory cases. The awareness of these entities and early recognition are critical to optimizing outcomes.<\/jats:p>","DOI":"10.3390\/medicina62030578","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:50:36Z","timestamp":1773921036000},"page":"578","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary Complications of Cancer Therapy: Clinical Presentations, Imaging Patterns, and Management Strategies"],"prefix":"10.3390","volume":"62","author":[{"given":"Bilal","family":"Zafar","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care & Sleep Medicine, McGovern Medical School at UTHealth, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-1280","authenticated-orcid":false,"given":"Tasmea","family":"Haque","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care & Sleep Medicine, McGovern Medical School at UTHealth, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9277-0680","authenticated-orcid":false,"given":"Miranda","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Sleep Medicine, Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA 94305, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-4039","authenticated-orcid":false,"given":"Lara","family":"Bashoura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1202-4121","authenticated-orcid":false,"given":"Maria","family":"Azhar","sequence":"additional","affiliation":[{"name":"Bayhealth Medical Group (Kent Campus), Dover, DE 19901, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-3945","authenticated-orcid":false,"given":"Saadia A.","family":"Faiz","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","unstructured":"National Institutes of Health (2025). Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/annonc\/mdj057","article-title":"Pulmonary toxicity from novel antineoplastic agents","volume":"17","author":"Dimopoulou","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cherri, S., Noventa, S., Fanelli, M., Calandra, G., Prochilo, T., Bna, C., Savelli, G., and Zaniboni, A. (2021). Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers, 13.","DOI":"10.3390\/cancers13051052"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.36401\/JIPO-24-12","article-title":"Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies","volume":"7","author":"Chan","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","volume":"25","author":"Long","year":"2020","journal-title":"Respirology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-02505-2_6","article-title":"Immune-Related Adverse Events: Pneumonitis","volume":"995","author":"Jain","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clon.2023.07.003","article-title":"Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer","volume":"35","author":"Altan","year":"2023","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_10","first-page":"631","article-title":"Therapy-induced toxicity of the lungs: An overview","volume":"29","author":"Charpidou","year":"2009","journal-title":"Anticancer. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJM199008093230604","article-title":"Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood","volume":"323","author":"Hasleton","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ccm.2016.12.012","article-title":"Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy","volume":"38","author":"Possick","year":"2017","journal-title":"Clin. Chest Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17476348.2026.2631816","article-title":"When cancer treatment affects the lungs: A clinical overview on pulmonary toxicity induced by new cancer drugs","volume":"20","author":"Komninos","year":"2026","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(10)70208-4","article-title":"Management of uncommon chemotherapy-induced emergencies","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.86.5.723","article-title":"Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids","volume":"86","author":"White","year":"1984","journal-title":"Chest"},{"key":"ref_17","unstructured":"Brandt, J.P., and Gerriets, V. (2023). Bleomycin. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1164\/rccm.201606-1235IM","article-title":"Pulmonary Radiation Recall Induced by Gemcitabine","volume":"194","author":"Faiz","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/resp.12665","article-title":"Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study","volume":"21","author":"Hamada","year":"2016","journal-title":"Respirology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.0767-3981.2003.00206.x","article-title":"Gemcitabine-induced severe pulmonary toxicity","volume":"18","author":"Barlesi","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Li, S., Miao, W., Tao, Q., Sun, J., Huang, Z., Zhou, Y., and Jiang, H. (2026). Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease. Naunyn Schmiedebergs Arch. Pharmacol.","DOI":"10.1007\/s00210-026-05016-2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","article-title":"Methotrexate and interstitial lung disease: Controversies and questions. A narrative review of the literature","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"ref_24","first-page":"321","article-title":"Drug-induced pulmonary disease. Part 1: Cytotoxic drugs","volume":"133","author":"Cooper","year":"1986","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccm.2004.05.006","article-title":"Drug-induced and iatrogenic infiltrative lung disease","volume":"25","author":"Camus","year":"2004","journal-title":"Clin. Chest Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108336","DOI":"10.1016\/j.rmed.2025.108336","article-title":"Noninfectious pulmonary complications after hematopoietic cell transplantation: A comprehensive review","volume":"248","author":"Bertini","year":"2025","journal-title":"Respir. Med."},{"key":"ref_27","first-page":"1103","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer","volume":"32","author":"Tamiya","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: A retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3892\/ijo.2023.5570","article-title":"Anti-PD-1\/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)","volume":"63","author":"Hu","year":"2023","journal-title":"Int. J. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated with Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1634\/theoncologist.2018-0352","article-title":"Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors","volume":"24","author":"Asher","year":"2019","journal-title":"Oncologist"},{"key":"ref_35","first-page":"101131","article-title":"Diffuse alveolar hemorrhage with nivolumab monotherapy","volume":"30","author":"Shannon","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1159\/000526141","article-title":"Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Respiration"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"108831","DOI":"10.1016\/j.lungcan.2025.108831","article-title":"Immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer patients with preexisting pulmonary emphysema or interstitial lung abnormalities","volume":"210","author":"Chen","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5811\/WESTJEM.20305","article-title":"Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review","volume":"26","author":"Li","year":"2025","journal-title":"West. J. Emerg. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.36401\/JIPO-20-22","article-title":"Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis","volume":"3","author":"Lai","year":"2020","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients with Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"oyaf228","DOI":"10.1093\/oncolo\/oyaf228","article-title":"Immuno-OncologyThe adverse event of interstitial lung disease in patients treated with antibody-drug conjugates","volume":"30","author":"Fang","year":"2025","journal-title":"Oncologist"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103960","DOI":"10.1016\/j.critrevonc.2023.103960","article-title":"Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis","volume":"184","author":"Zhu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e473916","DOI":"10.1200\/EDBK-25-473916","article-title":"Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies","volume":"45","author":"Jain","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13058-025-02151-1","article-title":"Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: A retrospective cohort study","volume":"27","author":"Azhar","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2022.07.014","article-title":"Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure","volume":"174","author":"Yoon","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","article-title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis","volume":"36","author":"Rugo","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_52","unstructured":"(2026, January 10). Administration FaD. PADCEV EJFV- Enfortumab Vedotin, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug Saf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2000279","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14740338.2022.2110235","article-title":"Interstitial pneumonitis associated with EGFR\/ALK tyrosine kinase inhibitors used in non-small cell lung cancer: An observational, retrospective, pharmacovigilance study","volume":"22","author":"Ma","year":"2023","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-Induced Lung Injury: Assessment and Management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104461","DOI":"10.1016\/j.critrevonc.2024.104461","article-title":"Pathogenic mechanisms and latest therapeutic approaches for radiation-induced lung injury: A narrative review","volume":"202","author":"Chang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","article-title":"Radiotherapy toxicities: Mechanisms, management, and future directions","volume":"405","author":"Verginadis","year":"2025","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Arroyo-Hernandez, M., Maldonado, F., Lozano-Ruiz, F., Munoz-Montano, W., Nunez-Baez, M., and Arrieta, O. (2021). Radiation-induced lung injury: Current evidence. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-020-01376-4"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"110837","DOI":"10.1016\/j.radonc.2025.110837","article-title":"Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline","volume":"207","author":"Ruysscher","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chopra, A., Hu, K., Judson, M.A., and Feller-Kopman, D. (2025). Clinical approach to a pleural effusion. Chest, online ahead of print.","DOI":"10.1016\/j.chest.2025.11.022"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Harding, W.C., Halawa, A.R., Aiche, M.M., Zafar, B., Ali, H.R., Bashoura, L., and Faiz, S.A. (2025). Pleural Effusion: Shedding Light on Pleural Disease Beyond Infection and Malignancy. Medicina, 61.","DOI":"10.3390\/medicina61030443"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/thoraxjnl-2021-217959","article-title":"Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: Systematic review and meta-analysis","volume":"78","author":"Kassirian","year":"2023","journal-title":"Thorax"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"97623","DOI":"10.18632\/oncotarget.18824","article-title":"Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/0284186X.2016.1176248","article-title":"Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy","volume":"55","author":"Deek","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_66","first-page":"1754","article-title":"Pleural Disease","volume":"378","author":"Light","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","article-title":"Pulmonary complications of novel antineoplastic agents for solid tumors","volume":"133","author":"Vahid","year":"2008","journal-title":"Chest"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MCP.0000000000000060","article-title":"Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome","volume":"20","author":"Faiz","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.1997.15.9.3149","article-title":"Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer","volume":"15","author":"Piccart","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy","volume":"17","author":"Falcon","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.2169\/internalmedicine.7219-21","article-title":"Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab","volume":"60","author":"Sawada","year":"2021","journal-title":"Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Terashima, T., Iwami, E., Shimada, T., Kuroda, A., Matsuzaki, T., Nakajima, T., Sasaki, A., and Eguchi, K. (2020). IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: A case report. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-1150-x"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2302158","DOI":"10.1183\/13993003.02158-2023","article-title":"Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors","volume":"63","author":"Grynblat","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1513\/AnnalsATS.202108-963CME","article-title":"Transfusion-related Acute Lung Injury: 36 Years of Progress (1985\u20132021)","volume":"19","author":"Toy","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/ALN.0000000000001506","article-title":"Risk Factors and Clinical Outcomes Associated with Perioperative Transfusion-associated Circulatory Overload","volume":"126","author":"Clifford","year":"2017","journal-title":"Anesthesiology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMra2116777","article-title":"Cryptogenic Organizing Pneumonia","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","first-page":"20160723","article-title":"Radio-pathological correlation of organizing pneumonia (OP): A pictorial review","volume":"90","author":"Kahkouee","year":"2017","journal-title":"Br. J. Radiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","article-title":"Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement","volume":"211","author":"Podolanczuk","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.202303-0410OC","article-title":"Long-Term Follow-Up of Interstitial Lung Abnormality: Implication in Follow-Up Strategy and Risk Thresholds","volume":"208","author":"Park","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/578\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:30:09Z","timestamp":1773923409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicina62030578"],"URL":"https:\/\/doi.org\/10.3390\/medicina62030578","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}